NEU.AX · NEUREN PHARMACEUTICALS LIMITED
Australia · RS rating 81 · As of 2026-10-14
| Price | 19.40 AUD |
|---|---|
| 1-day change | -1.2% |
| RS rating (overall / 1M / 3M / 12M) | 81 / 42 / 82 / 62 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 35 / 43 / 23 |
| Industry group (rank) | Medical-Biomed/Biotech (–) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | – |
| Distance from 52-week high | +17.9% |
| Market cap (USD) | $1.8B |